THERE are exciting developments in glaucoma research, but the medical treatment of noninflammatory types of chronic glaucoma continues to be primarily with drugs which induce miosis in the normal eye. In recent years, much has been learned about these drugs; a better understanding of the pathogenesis of chronic glaucoma has been reached, and there have been improvements in diagnosis and evaluation of treatment. As a result, miotic therapy no longer is purely symptomatic, with the dosage determined on a trial-and-error basis. It is the purpose of the present report to review some recent developments, particularly as they apply to the treatment of chronic glaucoma.
The hypotensive effect of these drugs on glaucomatous eyes cannot be merely a matter of contraction of the intraocular muscles, because alterations in ocular tension occur which cannot be explained on such a simple mechanical basis; however, the mechanism, intensity, and duration of action of these
SWAN KC. MIOTIC THERAPY OF CHRONIC GLAUCOMA—CHANGING TRENDS. AMA Arch Ophthalmol. 1953;49(4):419–430. doi:10.1001/archopht.1953.00920020429006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: